Increasing Patient Involvement in Drug Development

Abstract

As health care systems continue to evolve and establish patients as the primary stakeholder in their health care decision making, the pharmaceutical industry will need to be innovative to demonstrate the value of their products relative to the outcomes experienced by patients. Pharmaceutical companies should recognize the value of involving patients across the entire product life cycle and work to transform present perceptions and practices throughout their organizations.

Hemophilia trials in the twenty‐first century: Defining patient important outcomes

“…In brief, choosing and collecting PIOs and PROs is becoming an essential component of clinical trials . Each trial should measure PIOs, which can be clinical or PROs.…”

“…[60][61][62][63][64][65][66][67] In brief, choosing and collecting PIOs and PROs is becoming an essential component of clinical trials. [68][69][70] Each trial should measure PIOs, which can be clinical or PROs. It is now recognized that patients have a unique perspective and will consider issues differently than clinicians, scientists, regulators, and manufacturers.…”

Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights From a Discrete Choice Experiment in Migraine

“…The development of a treatment to help improve patients' lives should be rooted in a solid understanding of the challenges these patients face in their daily activities, their needs and the compromises they are willing to make to obtain relief. To ensure the creation of valuable treatments, all aspects of the healthcare system and treatment decisions need to be aligned with the needs of patients (1). At present, there are limited data describing the scope and overall bene t of existing patient-centred drug development activities (2), and the assessment of patients' preferences for treatment characteristics in this setting would increase the current evidence on the impact of diseases to support decision-making processes in the eld of public policies and research and development in pharmaceutical industries.…”

Person-Centered Healthcare - moving from rhetoric to methods, through implementation to outcomes

“…As a function of such influence and advocacy, patients have become progressively involved in their own care planning and many contribute prominently to clinical services reconfiguration and de novo service planning as part of patient and public involvement activities [5][6][7][8][9][10][11]. Patients now advise both local and national governments and also the pharmaceutical and healthcare technology Industriesin the latter case becoming increasingly involved in clinical trial design and in medicines development itself [12][13][14][15][16].…”